Skip to main content
. 2016 May 25;12(1):663–669. doi: 10.3892/ol.2016.4627

Table IV.

Adverse events leading to the discontinuation of taxanes.

Adverse event Paclitaxel, n (%) Docetaxel, n (%)
Sensory neuropathy 12 (6.3) 1 (1.0)
Nail pain   1 (0.5) 0 (0.0)
Thrombocythemia   1 (0.5) 0 (0.0)
Neutropenia   1 (0.5) 0 (0.0)
Fatigue   1 (0.5) 0 (0.0)
Fever   1 (0.5) 0 (0.0)
Intestinal pneumonia   1 (0.5) 0 (0.0)
Edema   1 (0.5) 7 (6.8)
Obstruction of nasolacrimal canal   0 (0.0) 1 (1.0)
Muscular pain   0 (0.0) 1 (1.0)
Heart failure   0 (0.0) 1 (1.0)
Total   19 (10.0) 13 (12.6)